Werewolf Therapeutics, Inc. (HOWL)
0.978
-0.01
(-1.06%)
USD |
NASDAQ |
Sep 11, 12:26
Werewolf Therapeutics Enterprise Value : 26.05M for Sept. 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 10, 2026 | 26.05M |
| September 09, 2026 | 24.91M |
| September 08, 2026 | 25.64M |
| September 04, 2026 | 24.97M |
| September 03, 2026 | 23.88M |
| September 02, 2026 | 26.53M |
| September 01, 2026 | 24.55M |
| August 31, 2026 | 23.74M |
| August 28, 2026 | 23.86M |
| August 27, 2026 | 25.19M |
| August 26, 2026 | 26.07M |
| August 25, 2026 | 21.27M |
| August 24, 2026 | 20.94M |
| August 21, 2026 | 20.46M |
| August 20, 2026 | -1.031M |
| August 19, 2026 | -2.095M |
| August 18, 2026 | -2.100M |
| August 17, 2026 | -2.280M |
| August 14, 2026 | -2.319M |
| August 13, 2026 | -3.228M |
| August 12, 2026 | -3.427M |
| August 11, 2026 | -3.340M |
| August 10, 2026 | -3.422M |
| August 07, 2026 | -2.688M |
| August 06, 2026 | -2.411M |
| Date | Value |
|---|---|
| August 05, 2026 | -2.450M |
| August 04, 2026 | -1.838M |
| August 03, 2026 | -4.122M |
| July 31, 2026 | -4.827M |
| July 30, 2026 | 2.332M |
| July 29, 2026 | 0.3686M |
| July 28, 2026 | -0.1514M |
| July 27, 2026 | 0.043M |
| July 24, 2026 | -1.235M |
| July 23, 2026 | -4.482M |
| July 22, 2026 | -4.234M |
| July 21, 2026 | -4.346M |
| July 20, 2026 | -4.102M |
| July 17, 2026 | -4.102M |
| July 16, 2026 | -4.107M |
| July 15, 2026 | -5.488M |
| July 14, 2026 | -5.264M |
| July 13, 2026 | -5.390M |
| July 10, 2026 | -2.402M |
| July 09, 2026 | -3.592M |
| July 08, 2026 | -4.501M |
| July 07, 2026 | -5.269M |
| July 06, 2026 | -6.435M |
| July 02, 2026 | -5.444M |
| July 01, 2026 | -4.832M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.46B |
| Oncolytics Biotech, Inc. | 92.55M |
| Sangamo Therapeutics, Inc. | 56.12M |
| Sarepta Therapeutics, Inc. | 2.425B |
| Anixa Biosciences, Inc. | 80.15M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.67M |
| Revenue (Quarterly) | 21.00M |
| Total Expenses (Quarterly) | 17.33M |
| EPS Diluted (Quarterly) | 0.0755 |
| Gross Profit Margin (Quarterly) | 88.32% |
| Profit Margin (Quarterly) | 17.48% |
| Earnings Yield | -75.52% |
| Normalized Earnings Yield | -66.11 |